Biotech News
ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing
gsk.com2026-05-06 14:28 EST
VH184, the first, third‑generation integrase inhibitor in development shows potential for up to twice-yearly dosing intervals